The reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.22BUSD
vs all stocks (USD)
Updated Sep 28, 2026
Revenue (TTM)
587.90MUSD
vs all stocks (USD)
Updated Sep 28, 2026
Profit Margin
-12.40%
vs Diagnostics & Research peers
Updated Sep 28, 2026
Beta
1.50x
vs all stocks
Updated Sep 28, 2026
52-Week Change
11.56%
vs all stocks
Updated Sep 28, 2026
Market Capitalization
1.22BUSD
vs all stocks (USD)
Updated Sep 28, 2026
Enterprise Value
1.32BUSD
vs all stocks (USD)
Updated Sep 28, 2026
Forward P/E
-5.96x
vs Diagnostics & Research peers
Updated Sep 28, 2026
Price to Sales (TTM)
2.08x
vs Diagnostics & Research peers
Updated Sep 28, 2026
Price to Book (MRQ)
1.03x
vs Diagnostics & Research peers
Updated Sep 28, 2026
Enterprise to Revenue
2.25x
vs Diagnostics & Research peers
Updated Sep 28, 2026
Enterprise to EBITDA
-16.90x
vs Diagnostics & Research peers
Updated Sep 28, 2026
Gross Margin
48.92%
vs Diagnostics & Research peers
Provider-reported. Gross Profit (TTM) ÷ Revenue (TTM) on this page gives 19.47%.Updated Sep 28, 2026
Profit Margin
-12.40%
vs Diagnostics & Research peers
Updated Sep 28, 2026
Operating Margin
-15.31%
vs Diagnostics & Research peers
Updated Sep 28, 2026
Return on Assets (TTM)
-5.52%
vs Diagnostics & Research peers
Updated Sep 28, 2026
Return on Equity (TTM)
-5.88%
vs Diagnostics & Research peers
Updated Sep 28, 2026
Revenue (TTM)
587.90MUSD
vs all stocks (USD)
Updated Sep 28, 2026
Revenue per Share (TTM)
0.7540USDUpdated Sep 28, 2026
Quarterly Revenue Growth
4.30%
vs Diagnostics & Research peers
Updated Sep 28, 2026
Gross Profit (TTM)
114.48MUSD
vs all stocks (USD)
Updated Sep 28, 2026
EBITDA (TTM)
-78.17MUSD
vs all stocks (USD)
Updated Sep 28, 2026
Net Income (TTM)
-72.89MUSD
vs all stocks (USD)
Updated Sep 28, 2026
Quarterly Earnings Growth (YoY)
4.32%
vs Diagnostics & Research peers
Updated Sep 28, 2026
Operating Cash Flow (TTM)
-123.38MUSD
vs all stocks (USD)
Updated Sep 28, 2026
Levered Free Cash Flow (TTM)
54.76MUSD
vs all stocks (USD)
Updated Sep 28, 2026
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026
Trailing Annual Dividend Yield
0.00%
vs all stocks
Updated Sep 28, 2026
Payout Ratio
0.00%
vs Diagnostics & Research peers
Updated Sep 28, 2026
Revenue
606.88MUSDFY2025 · Dec 31, 2025
Cost of Goods Sold
400.94MUSDFY2025 · Dec 31, 2025
Gross Profit
205.94MUSDFY2025 · Dec 31, 2025
Operating Income
-218.99MUSD
vs all stocks (USD)
FY2025 · Dec 31, 2025
Pre-tax Income
-241.36MUSDFY2025 · Dec 31, 2025
Income Tax Expense
-15.71MUSDFY2025 · Dec 31, 2025
Net Income
-225.68MUSDFY2025 · Dec 31, 2025
EBIT
-132.90MUSDFY2025 · Dec 31, 2025
EBITDA (Income Statement)
-142.42MUSDFY2025 · Dec 31, 2025
Research & Development
124.03MUSDFY2025 · Dec 31, 2025
Selling, General & Administrative
223.00MUSDFY2025 · Dec 31, 2025
Non-operating Interest Income
14.81MUSDFY2025 · Dec 31, 2025
Non-operating Interest Expense
108.46MUSDFY2025 · Dec 31, 2025
EPS (Basic)
-0.3000USDFY2025 · Dec 31, 2025
EPS (Diluted)
-0.3000USDFY2025 · Dec 31, 2025
Basic Shares Outstanding
751.13MSharesFY2025 · Dec 31, 2025
Diluted Shares Outstanding
751.13MSharesFY2025 · Dec 31, 2025
Net Income from Continuing Operations
-225.68MUSDFY2025 · Dec 31, 2025
Operating Cash Flow
-60.19MUSDFY2025 · Dec 31, 2025
Free Cash Flow
-60.48MUSDDerived from operating cash flow minus capital expenditure. This filing charges 91.63M of depreciation against 287K of capital expenditure, and its own free-cash-flow line reads -190.82M.FY2025 · Dec 31, 2025
Cash & Cash Equivalents (End of Period)
382.74MUSDFY2025 · Dec 31, 2025
Income Tax Paid
24.46MUSDFY2025 · Dec 31, 2025
Interest Paid
37.94MUSDFY2025 · Dec 31, 2025
Starting Profit (CF Statement)
-225.68MUSDFY2025 · Dec 31, 2025
Depreciation & Amortization
91.63MUSDFY2025 · Dec 31, 2025
Deferred Taxes (CF)
-15.00MUSDFY2025 · Dec 31, 2025
Stock-based Compensation
10.71MUSDFY2025 · Dec 31, 2025
Other Non-cash Items
71.49MUSDFY2025 · Dec 31, 2025
Change in Accounts Receivable (CF)
30.21MUSDFY2025 · Dec 31, 2025
Change in Accounts Payable (CF)
-14.22MUSDFY2025 · Dec 31, 2025
Change in Other Assets/Liabilities
-9.34MUSDFY2025 · Dec 31, 2025
Capital Expenditures
287.00KUSDFY2025 · Dec 31, 2025
Net Acquisitions
190.10MUSDFY2025 · Dec 31, 2025
Sale of Investments
52.18MUSDFY2025 · Dec 31, 2025
Net Investing Cash Flow
242.57MUSDFY2025 · Dec 31, 2025
Long-term Debt Issuance
33.03MUSDFY2025 · Dec 31, 2025
Long-term Debt Payments
-103.79MUSDFY2025 · Dec 31, 2025
Common Stock Repurchase
-47.04MUSDFY2025 · Dec 31, 2025
Net Financing Cash Flow
-117.80MUSDFY2025 · Dec 31, 2025
Shares Outstanding
745.95MSharesUpdated Sep 28, 2026
Float Shares
323.73MSharesUpdated Sep 28, 2026
Shares Short
35.99MSharesUpdated Sep 28, 2026
Short Ratio
12.18days
vs all stocks
Updated Sep 28, 2026
Short % of Shares Outstanding
8.68%
vs all stocks
Provider-reported. Shares Short ÷ Shares Outstanding on this page gives 4.82%.Updated Sep 28, 2026
% Held by Insiders
50.52%
vs all stocks
Updated Sep 28, 2026
% Held by Institutions
27.56%
vs all stocks
Updated Sep 28, 2026
Total Cash (MRQ)
300.76MUSD
vs all stocks (USD)
Updated Sep 28, 2026
Total Cash per Share (MRQ)
0.4030USDUpdated Sep 28, 2026
Total Debt (MRQ)
398.08MUSD
vs all stocks (USD)
Updated Sep 28, 2026
Total Debt to Equity (MRQ)
0.3362x
vs Diagnostics & Research peers
Updated Sep 28, 2026
Current Ratio (MRQ)
3.35x
vs Diagnostics & Research peers
Updated Sep 28, 2026
Book Value per Share (MRQ)
1.59USDUpdated Sep 28, 2026
Total Assets
1.93BUSD
vs all stocks (USD)
FY2025 · Dec 31, 2025
Total Current Assets
581.88MUSDFY2025 · Dec 31, 2025
Total Liabilities
663.99MUSDFY2025 · Dec 31, 2025
Total Non-current Assets
1.35BUSDFY2025 · Dec 31, 2025
Total Non-current Liabilities
517.31MUSDFY2025 · Dec 31, 2025
Total Current Liabilities
146.68MUSDFY2025 · Dec 31, 2025
Cash & Cash Equivalents
369.07MUSDFY2025 · Dec 31, 2025
Accounts Receivable
90.25MUSDFY2025 · Dec 31, 2025
Inventory
65.82MUSDFY2025 · Dec 31, 2025
Accounts Payable
41.10MUSDFY2025 · Dec 31, 2025
Short-term Debt
22.86MUSDFY2025 · Dec 31, 2025
Long-term Debt
373.92MUSDFY2025 · Dec 31, 2025
Other Non-current Liabilities
11.60MUSDFY2025 · Dec 31, 2025
Common Stock (Book)
7.90MUSDFY2025 · Dec 31, 2025
Retained Earnings
-2.29BUSDFY2025 · Dec 31, 2025
Total Shareholders' Equity
1.27BUSD
vs all stocks (USD)
FY2025 · Dec 31, 2025
Treasury Stock
3.18MUSDFY2025 · Dec 31, 2025
52-Week Low
0.9800USDUpdated Sep 28, 2026
52-Week High
1.75USDUpdated Sep 28, 2026
52-Week Change
11.56%
vs all stocks
Updated Sep 28, 2026
Beta
1.50x
vs all stocks
Updated Sep 28, 2026
50-Day MA
1.46USDUpdated Sep 28, 2026
200-Day MA
1.32USDUpdated Sep 28, 2026
Avg 10-Day Volume
2.42MSharesUpdated Sep 28, 2026
Avg 30-Day Volume
2.86MSharesUpdated Sep 28, 2026
Diluted EPS (TTM)
-0.0700USDUpdated Sep 28, 2026
Other Income / Expense
71.27MUSDFY2025 · Dec 31, 2025
1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Much of what it owns is goodwill from past deals, large next to its equity.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Price-to-book is 1.03×, lower than 95% of its Diagnostics & Research peers (median 3.02×)Notable